What is the Purpose of this Study?
The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROLTM VENOUS VCD 6F-12F in sealing femoral venous access sites in patients who have undergone endovascular procedures in a real-world setting.
Eligibility
- 1. Able and willing to provide informed consent and to complete a follow-up visit at 14 ± 7 days post-procedure.
- 2. Individuals undergoing catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs.
- 3. Individuals who are candidates to have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.
- 4. At the time of enrollment, the Investigator deems the subject a candidate for same-day discharge (SDD) per standard of care (no procedure related events/complications e.g., no new pericardial effusion, post-procedure diuresis not needed, etc.).
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
Mobilization and Outcomes after VEnous Closure ? A Prospective Registry of Real-World Outcomes/Usage/Evidence for the MYNX CONTROL? VENOUS Vascular Closure Device 6F-12F